Quick Answer
Bolt Biotherapeutics, Inc. reported Total Revenue of $7.70 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $7.70M | +0.1% |
| 2024 | $7.69M | -2.4% |
| 2023 | $7.88M | +37.5% |
| 2022 | $5.73M | +354.7% |
| 2021 | $1.26M | +445.5% |
| 2020 | $231.0K | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.17M | +90.1% | +20.2% |
| June 30, 2025 | $1.80M | +41.5% | +47.6% |
| March 31, 2025 | $1.22M | -76.8% | +7.1% |
| September 30, 2024 | $1.14M | -54.9% | -10.5% |
| June 30, 2024 | $1.27M | -11.0% | -75.8% |
| March 31, 2024 | $5.27M | +188.8% | +108.6% |
| September 30, 2023 | $2.53M | +19.7% | +76.4% |
| June 30, 2023 | $1.43M | +2.9% | -21.5% |
- Bolt Biotherapeutics, Inc. showed an increase of +0.1% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2025 period, Bolt Biotherapeutics, Inc.’s total revenue has grown by 3231.2% (from $231.0 thousand to $7.70 million).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: